Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease
The protease inhibitors (PI) actively using for the treatment of chronic hepatitis C (CHC).The aim of this analysis was to evaluate the cost-effectiveness of narlaprevir and simeprevir in the CHC (genotype 1) therapy in treatment-naïve patients and relapses.Material and methods. Analysis of the cost...
Saved in:
Main Authors: | A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Journal Infectology
2016-04-01
|
Series: | Журнал инфектологии |
Subjects: | |
Online Access: | https://journal.niidi.ru/jofin/article/view/466 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
by: D. A. Gusev, et al.
Published: (2016-11-01) -
PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
by: A. V. Rudakova, et al.
Published: (2017-04-01) -
Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)
by: A. V. Rudakova, et al.
Published: (2017-06-01) -
COST-EFFECTIVENESS OF ANTIVIRAL THERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C (GENOTYPE 1) WITH VARIOUS SEVERITY OF FIBROSIS STAGE
by: A. V. Rudakova, et al.
Published: (2018-01-01) -
Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)
by: A. V. Rudakova, et al.
Published: (2016-02-01)